NEW YORK, NY / ACCESSWIRE / January 4, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=35342&wire=1
AFRM Shareholders Click Here: https://www.zlk.com/pslra-1/affirm-class-action-submission-form?prid=35342&wire=1
SGLY Shareholders Click Here: https://www.zlk.com/pslra-1/singularity-future-technology-lawsuit-submission-form?prid=35342&wire=1
* ADDITIONAL INFORMATION BELOW *
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 – October 4, 2022
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=35342&wire=1
According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger’s clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization (“EUA”) for the Company’s product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Affirm Holdings, Inc. (NASDAQ:AFRM)
AFRM Lawsuit on behalf of: investors who purchased February 12, 2021 – December 15, 2021
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/affirm-class-action-submission-form?prid=35342&wire=1
According to the filed complaint, during the class period, Affirm Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Affirm’s “buy-now, pay-later” service facilitated excessive consumer debt, regulatory arbitrage, and data harvesting; (ii) the foregoing subjected Affirm to a heightened risk of regulatory scrutiny and enforcement action; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Singularity Future Technology Ltd. (NASDAQ:SGLY)
SGLY Lawsuit on behalf of: investors who purchased February 12, 2021 – November 17, 2022
Lead Plaintiff Deadline : February 7, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/singularity-future-technology-lawsuit-submission-form?prid=35342&wire=1
According to the filed complaint, during the class period, Singularity Future Technology Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had misrepresented the true educational background of its former CEO, Yang Jie; 2) Yang Jie had an outstanding arrest warrant in China, had committed forgery, and was the largest shareholder and VP of Finance for a Nasdaq-listed lending company, China Commercial Credit (“CCC”), which failed after reporting massive losses; (3) there existed material related party transactions with SOS Information Technology New York Inc. (where Jie’s wife was Vice President) and Rich Trading, whose CEO was defendant Lei Nie, the husband of Singularity CFO Tuo Pan; (4) Singularity director John Levy had been a director at CCC from January 2013 through December 2016 as CCC failed amidst detailed allegations that Jie, when he was an executive and shareholder in CCC, misappropriated assets; (5) the Company lacked adequate internal controls, and as a result had a heightened risk of scrutiny and was ultimately subject to a United States Attorney’s Office for the Southern District of New York and SEC investigation and action as well as a potential delisting by NASDAQ; and (6) as a result, the Company’s statements during the class period about the historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company, and were materially false and misleading and lacked a factual basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/734081/CLASS-ACTION-UPDATE-for-EIGR-AFRM-and-SGLY-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders